Omega's FY 2007 sales rise 8% to 789.1M euros

Omega Pharma posted disappointing full-year 2007 sales due to a poor performance in the domestic market. The Belgian over-the-counter health care firm says income during the period rose 8% on the previous year to 789.1 million euros ($1.15 billion).

The firm's strongest performances were delivered by Omega Pharma France and by its organizations in southern, central and eastern Europe. The turnover generated beyond the home market increased 16% with growth of 6% in Belgium.

According to Omega, all core categories witnessed a double-digit or high single-digit growth in turnover. Revenues from Natural Remedies & Slimming, including brands like XLS, Davitamon, Silence and Aflubin, showed the strongest growth, up 82%, although these sales increased only 12% in the domestic market.